To all...an interesting note
April 30,1996 Kostech Research Bulletin
Viragen Inc. (OTC:BB:VRGN) is an emerging biopharmaceutical
company engaged in the research, manufacture, and clinical
study of natural human alpha interferons for the treatment
of various viral diseases and immune disorders, including
HIV/AIDS, hepatitis B & C, and multiple sclerosis. Viragen
manufactures Alpha Leukoferon in its Florida facility and
is currently constructing a new facility in the United
Kingdom to produce Omniferon(tm) in collaboration with
Scottish authorities.
On March 18 this year, Viragen announced that it had
closed a $6 million privately placed equity financing of
its majority owned subsidiary, Sector Associates Ltd.,
to be renamed Viragen (Europe) Ltd. A portion of these
proceeds will be used to complete the company's European
plant located in Edinburgh, Scotland. This state of the
art manufacturing facility will produce Omniferon(tm),
a natural human alpha interferon. The company plans to
undertake clinical studies in Europe for testing Omniferon
in the treatment of such diseases as multiple sclerosis,
HIV/AIDS, hepatitis B & C and certain cancers. A portion
of the proceeds will also be used to fund continuing
research and development here in the U.S.
This past year has seen Viragen realize its stated objectives
and take some giant steps forward. The engagement of Mr.
Robert Zeiger as Viragen's CEO, COO and as director has
attracted the attention of the drug industry and its
observers. Mr Zeigler is regarded as a symbol of managerial
expertise, credibility and capability having served as the
General Manager of Glaxo Pharmaceuticals for 10 years. The
fact that Bob joined Viragen after managing a multi-billion
dollar subsidiary of the world's largest pharmaceutical
company speaks for itself. Now most recently, Jay
Sawardeker joins Viragen as Executive Vice President.
Dr. Sawardeker has served in various senior technical
management capacities in the pharmaceutical industry over
the past 25 years. His last position was with Glaxo holdings
PLC, as Corporate Vice President-Worldwide Quality.
This company has shown strong growth potential and has been
able to attract several private placements which is an
excellent indicator of where its heading.
Contact: Steven Sanders 305-557-6000
OTC:BB:VRGN is currently trading around 5 1/4
Tom Kosta
Kostech SmallCap Research
kostech.com
COPYRIGHT (c) 1996 by Kostech SmallCap Research. ALL RIGHTS RESERVED.
While it is our intent to research and locate companies which will
provide profitable investments, we are not liable for any investment
decisions by our subscribers. We are simply a compiler and filter of
information. Past performance of previously featured companies does
not guarantee the future success of a currently featured company.
Check with a licensed financial advisor before reaching any investment
decision. |
